Comparative rates of adverse events with different formulations of intravenous iron

Authors

  • Maureen M. Okam,

    Corresponding author
    1. Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts
    2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • Division of Hematology, Brigham and Women's Hospital, 75 Francis Street, Mid-campus 3, Boston, MA 02115
    Search for more papers by this author
  • Elyse Mandell,

    1. Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts
    2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    Search for more papers by this author
  • Nathanael Hevelone,

    1. Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Rachel Wentz,

    1. Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Ainsley Ross,

    1. Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Gregory A. Abel

    1. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    2. Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    Search for more papers by this author

  • Conflict of interest: Nothing to report.

No abstract is available for this article.

Ancillary